Phase II Study of Stereotactic Body Radiation Therapy and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary)
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 09 Jan 2019 Status changed from not yet recruiting to recruiting.
- 03 Dec 2018 Planned initiation date changed from 1 Feb 2019 to 1 May 2019.